November 17, 2020

Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): antibodies

[Pre-print, not peer reviewed] The cumulative incidence of SARS-CoV-2 infection may be underestimated by using cross-sectional data from serology tests without adjusting for waning antibodies. By estimating the average time from seroconversion to seroreversion and combining with population-level cross sectional data, Shioda et al. calculated the cumulative incidence to be 27% in New York City and 9% in Connecticut (through the end of September 2020), while prior estimates were lower (22% and 6%, respectively).

Shioda et al. (Nov 16, 2020). Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies. Pre-print downloaded Nov 17 from https://doi.org/10.1101/2020.11.13.20231266